PhD defence by Sven Weller

On Tuesday 18 January, Sven Weller will defend his PhD thesis: "Synthesis of antibody conjugated polymeric nanoparticles for controlled activation, priming and tracking of T cells in the context of cancer immunotherapy"

Time: Tuesday 18 January, at 13:00

Place: Building 303, aud. 43

- Zoom sign up:

Please be aware that the PhD defence may be recorded - This will also be informed at the beginning of the PhD defence. 

Professor Thomas Lars Andresen
Researcher Gael Clergeaud Veiga

Associate Professor Jonas R. Henriksen, DTU Health Tech
Professor Torben Moos, Aalborg Universitet
Lecturer/Group Leader Nazila Kamaly, Imperial College London

Chairperson at defence:
Associate Professor Paul Kempen

Cancer immunotherapy has shown promising results in clinical studies by reactivating the body's immune system to fight cancer. One specific approach is adoptive cell transfer (ACT) which includes the isolation, activation, reproduction and reinfusion of T cells from the patient. Current approaches often come with severe side effects, which is why improvements of this type of therapy are highly needed.  In this regard, antibody-conjugated nanoparticles have shown great potential over the last years due to their capabilities of delivering drugs to the site of disease. In this work nanosized particle systems were developed to improve different stages of ACT, which include the activation, boosting after reinfusion, and tracking of the T cells. We demonstrate how to better control T cell activation by using nanoparticles with precisely engineered and well-oriented activation antibodies on the surface. In addition, a nanosized particle was developed to enhance the T cell performance after infusion, which releases a signaling molecule that promotes the T cell function and contains an immobilized antibody that blocks immune suppressive mechanisms from the tumor. Finally, another approach was used utilizing fluorescent nanoparticles to label T cells for tracking purposes, providing a possible solution to identify the biodistribution of T cells after infusion. In conclusion, three different nanoparticle systems have been developed highlighting the importance of well-engineered antibody-nanoparticle conjugates for further improving cellular therapies.


Tue 18 Jan 22
13:00 - 16:00


DTU Sundhedsteknologi


Bldg. 303A, aud. 43 and zoom.